MENLO PARK, Calif.--(BUSINESS WIRE)--CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), a preclinical stage biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that the Company will release its fourth quarter 2016 financial results on Wednesday, March 22, 2017 and management will host a conference call for shareholders the same day at 2:00 p.m. (PST).
Conference Call Information:
Date: March 22, 2017
Time: 2:00 p.m. (PST)
Dial-in U.S. and Canada: 1-888-287-5516
Dial-in International: 1-719-457-2683
Conference ID# 3409008
An audio recording of the call will be available beginning at 5:00 p.m. (PST) on March 22, 2017, through 9:00 p.m. (PDT) on March 29, 2017. To access the recording please dial 1-844-512-2921 in the U.S. and Canada or 1-412-317-6671 internationally and reference Conference ID# 3409008.
CohBar (OTCQX: CWBR and TSXV: COB.U) is a preclinical stage biotechnology company focused on the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs for the treatment of age-related diseases. MBTs originate from the discovery by CohBar’s founders of a novel group of peptides within the mitochondrial genome, which regulate metabolism and cell death and whose biological activity declines with age. CohBar’s efforts focus on the development of these mitochondrial-derived peptides (MDPs) into clinically relevant MBTs that offer the potential to address a broad range of age-related diseases, including obesity, fatty liver disease (NASH), Type-2 diabetes, cancer, cardiovascular and neurodegenerative diseases. To date, the Company and its founders have discovered more than 50 biologically active mitochondrial peptides.
For additional company information, please visit www.cohbar.com.